Data Sheet 1_Impact of adjuvant immunotherapy on prognosis in esophageal squamous cell car

323 esophageal squamous cell carcinoma patients from a multicenter retrospective study, analyzed to determine the efficacy of postoperative adjuvant immunotherapy. The study, authored by Jiayi Geng and last updated in March 2026, found significant survival benefits for non-pCR patients. Results include 2-year overall survival rates of 95.8% versus 84.4% for patients receiving adjuvant immunotherapy.

Use Cases

• Modeling overall survival (OS) outcomes based on adjuvant immunotherapy treatment status.
• Analyzing disease-free survival (DFS) differences between patient groups with and without pathological complete response (pCR).
• Investigating cancer-specific survival (CSS) benefits from adjuvant immunochemotherapy versus monotherapy.
• Evaluating treatment efficacy using inverse probability of treatment weighting (sIPTW) to balance baseline characteristics.

Strengths

• Includes 323 patient records from a multicenter retrospective study.
• Reports specific 2-year survival rates (e.g., 95.8% OS for AIT group).
• Uses statistical methods like sIPTW to balance baseline characteristics.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• Data is contained in a DOCX file, which may require extraction and formatting for analysis.
• The retrospective study design may reflect inherent selection biases.

Provenance

Source

figshare, author Jiayi Geng.

Collection Method

Multicenter, retrospective study.

Time Range

null

Freshness

Last updated 2026-03-18 10:10:23.

Geography

null